ESSA Pharma Updates Terms of XenoTherapeutics Deal, Lowers Shareholder Payout and Adjourns Special Meeting to October 2025

Reuters

09/24

ESSA Pharma Updates Terms of XenoTherapeutics Deal, Lowers Shareholder Payout and Adjourns Special Meeting to October 2025

ESSA Pharma Inc. has announced an amendment to its previously disclosed agreement with XenoTherapeutics Inc. Under the revised terms, ESSA shareholders are now expected to receive approximately $0.12 per share in cash at closing, in addition to a contingent value right $(CVR)$ that could provide up to approximately $0.14 per share, depending on certain conditions. This update reflects adjustments for potential liabilities, associated expenses, and the company's latest cash balance estimates. The company stated that these changes were made in light of new financial information and will be detailed in supplemental proxy materials to be filed in due course. XOMA Royalty Corporation continues to act as structuring agent and intends to provide financing for the transaction. The special meeting to approve the amended agreement has been further adjourned to October 3, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief on September 24, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2569777136"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569777136\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569777136?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-24 18:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569777136","market":"nz","top_or_hot":-1,"title":"ESSA Pharma Updates Terms of XenoTherapeutics Deal, Lowers Shareholder Payout and Adjourns Special Meeting to October 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ESSA Pharma Updates Terms of XenoTherapeutics Deal, Lowers Shareholder Payout and Adjourns Special Meeting to October 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EPIX\">ESSA Pharma Inc.</a> has announced an amendment to its previously disclosed agreement with XenoTherapeutics Inc. Under the revised terms, ESSA shareholders are now expected to receive approximately $0.12 per share in cash at closing, in addition to a contingent value right <a href=\"https://laohu8.com/S/CVR\">$(CVR)$</a> that could provide up to approximately $0.14 per share, depending on certain conditions. This update reflects adjustments for potential liabilities, associated expenses, and the company's latest cash balance estimates. The company stated that these changes were made in light of new financial information and will be detailed in supplemental proxy materials to be filed in due course. XOMA Royalty Corporation continues to act as structuring agent and intends to provide financing for the transaction. The special meeting to approve the amended agreement has been further adjourned to October 3, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief on September 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ESSA Pharma Updates Terms of XenoTherapeutics Deal, Lowers Shareholder Payout and Adjourns Special Meeting to October 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nESSA Pharma Updates Terms of XenoTherapeutics Deal, Lowers Shareholder Payout and Adjourns Special Meeting to October 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-24 18:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ESSA Pharma Updates Terms of XenoTherapeutics Deal, Lowers Shareholder Payout and Adjourns Special Meeting to October 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EPIX\">ESSA Pharma Inc.</a> has announced an amendment to its previously disclosed agreement with XenoTherapeutics Inc. Under the revised terms, ESSA shareholders are now expected to receive approximately $0.12 per share in cash at closing, in addition to a contingent value right <a href=\"https://laohu8.com/S/CVR\">$(CVR)$</a> that could provide up to approximately $0.14 per share, depending on certain conditions. This update reflects adjustments for potential liabilities, associated expenses, and the company's latest cash balance estimates. The company stated that these changes were made in light of new financial information and will be detailed in supplemental proxy materials to be filed in due course. XOMA Royalty Corporation continues to act as structuring agent and intends to provide financing for the transaction. The special meeting to approve the amended agreement has been further adjourned to October 3, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief on September 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XOMA","symbol_name":"標記臨牀研究","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250924:nNDL53Zm9:1","article_id":"2569777136","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569777136","pubTimestamp":1758708052,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ESSA Pharma Inc. has announced an amendment to its previously disclosed agreement with XenoTherapeutics Inc. Under the revised terms, ESSA shareholders are now expected to receive approximately $0.12 per share in cash at closing, in addition to a contingent value right  that could provide up to approximately $0.14 per share, depending on certain conditions. This update reflects adjustments for potential liabilities, associated expenses, and the company's latest cash balance estimates. The company stated that these changes were made in light of new financial information and will be detailed in supplemental proxy materials to be filed in due course. XOMA Royalty Corporation continues to act as structuring agent and intends to provide financing for the transaction. The special meeting to approve the amended agreement has been further adjourned to October 3, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XOMA":"标记临床研究","BK4139":"生物科技","EPIX":"ESSA Pharma Inc."},"translate_title":"ESSA Pharma更新XenoTherapeutics交易条款，降低股东派息并将特别会议推迟至2025年10月","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XOMA":0.9,"EPIX":0.9},"content_text":"ESSA Pharma Updates Terms of XenoTherapeutics Deal, Lowers Shareholder Payout and Adjourns Special Meeting to October 2025\n    \n\nESSA Pharma Inc. has announced an amendment to its previously disclosed agreement with XenoTherapeutics Inc. Under the revised terms, ESSA shareholders are now expected to receive approximately $0.12 per share in cash at closing, in addition to a contingent value right $(CVR)$ that could provide up to approximately $0.14 per share, depending on certain conditions. This update reflects adjustments for potential liabilities, associated expenses, and the company's latest cash balance estimates. The company stated that these changes were made in light of new financial information and will be detailed in supplemental proxy materials to be filed in due course. XOMA Royalty Corporation continues to act as structuring agent and intends to provide financing for the transaction. The special meeting to approve the amended agreement has been further adjourned to October 3, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief on September 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}